X @The Wall Street Journal
The Wall Street Journal·2026-03-09 06:36
The combination of Roche’s investigational drug, giredestrant, with Pfizer’s Ibrance didn’t lead to a statistically significant improvement among patients with advanced breast cancer. https://t.co/CPwMZyeet2 ...